ArticleInternational journal of clinical and experimental pathology2017
Prognostic potential and oncogenic effects of UCH-L1 expression in hilar cholangiocarcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- UCHL1 Maintains MUC3A Stability through Deubiquitination to Activate the Downstream Pathways of EGFR, Driving Proliferation and Epithelial-Mesenchymal Transition in Extrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- UCHL1 Promoted Polarization of M1 Macrophages by Regulating the PI3K/AKT Signaling Pathway.Journal of inflammation research · 2022Article
- Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUCH-L1 has been implicated to playing a potential role in cancer development and progression. However, UCH-L1's role in hilar cholangiocarcinoma remains unclear.
methodsThe function of UCH-L1 in hilar cholangiocarcinoma was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival.
resultsIn the present study, UCH-L1 was overexpressed in 62.1% of patients with primary hilar cholangiocarcinoma. Overexpression of UCH-L1 is associated with large tumor size, advanced tumor stage, lymph node metastasis, advanced TNM stage, and high CA19-9 levels, and is also correlated with poor survival rates. Silencing of UCH-L1 inhibited proliferation, colony formation of hilar cholangiocarcinoma cells in vitro and suppressed tumor growth of hilar cholangiocarcinoma cells in vivo. We also observed that silencing of UCH-L1 decreased the phosphorylation level of Akt and PCNA in the xenograft experiments. DISCUSSION: Taken together, these findings suggest that UCH-L1 functions as an oncogene in the development and progression of hilar cholangiocarcinoma. UCH-L1 can serve as an independent prognostic factor and maybe a potential therapeutic target for patients with hilar cholangiocarcinoma.
Indexed as
Identifiers
31966423PMC6965845W3027609292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.